Johnson & Johnson (JNJ)

Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories are as dramatic as the current transformation of Teleflex Incorporated (NYSE: TFX). Once a darling of the "growth-at-any-cost" era, the Wayne, Pennsylvania-based company found itself [...]

Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall Street as a speculative "story stock" with a complex corporate structure, the company has pivoted sharply into a commercial powerhouse. As of early 2026, ImmunityBio is [...]

JNJ (NYSE: JNJ) to release Q1 earnings before bell on April 14. Analysts expect $2.67/share & $23.6B revenue. FDA approves TECNIS PureSee lens.

Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns.

The company is a picture of financial stability.

Robert Half provides staffing and consulting services to global clients across accounting, finance, IT, legal, and creative sectors.

Could this player be heading into a new era of growth?

ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology (EP), a

ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ system. The clearance marks the final

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded (patented) pharmaceutical imports. The announcement, timed to coincide with the first anniversary of "Liberation Day"—the administration's 2025

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2, the offer has now been pushed back to April 24, 2026. This delay, while framed as a standard procedural

The answer to the question might surprise many investors. It pays to be open-minded about risk.

These two high-yield heavyweights offer very different approaches.

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided the market with a compelling case study in strategic resilience. Reporting its third-quarter fiscal 2026 results, the company showcased

Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%.

These blue-chip stocks can make investors money if stagflation returns -- and also if it doesn't.

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed its legacy consumer health business and weathered the initial storm of its largest patent cliff in a decade, J&J has rebranded itself as a [...]

These dividend stocks are ones you can rest peacefully at night owning.

This healthcare leader can weather almost any storm.

Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its Pulsed Field Ablation (PFA) portfolio, the stock is experiencing a sharp intraday decline of 4.2% today, March 31, 2026. This move comes despite the recent [...]

Eli Lilly is much more than just a weight loss stock.

The healthcare leader has seen better times.

These companies help me sleep peacefully at night.